BlinkLab (ASX:BB1) recruited 54 out of 100 children for the initial phase of its US autism diagnostic clinical trial, according to a Tuesday filing with the Australian bourse.
The study aims to validate the BlinkLab Dx1 neurological test as a diagnostic aid for clinicians in early assessment of developmental disorders, the filing said.
The company is expected to complete enrolment and data analysis of the initial study by the third quarter of the year, per the filing.
Shares fell past 1% in afternoon trade Tuesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.